Form 4: Beyond Air Director Exercises and Reprices Stock Options

A Beyond Air director, Robert Carey, exercised and repriced a number of stock options on November 22, 2024, following a board-approved repricing.

Summary

• Robert Carey, a director at Beyond Air, Inc., engaged in multiple stock option transactions on November 22, 2024.
• These transactions involved the exercise of existing stock options and the repricing of other options.
• The board of directors approved a repricing of options, reducing the exercise price to $0.54 per share, which was the closing price of the company's common stock on that date.
• The repricing affected multiple tranches of options, with the original exercise prices ranging from $1.53 to $6.87.
• A total of 336,000 options were repriced to $0.54 per share.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment. It reports a standard corporate action of repricing stock options. While it could be seen as a positive for the director, it could also be seen as a negative for the company's performance.

Positives

• The repricing of stock options to the closing price of $0.54 may incentivize the director to work towards increasing the company's share price.
• The repricing of options could be seen as a positive move to align the director's interests with those of the shareholders.

Negatives

• The repricing of options could be seen as a negative signal, suggesting that the original option prices were unlikely to be reached.
• The repricing may dilute the value of existing shares if the options are exercised.

Risks

• The repricing of options could lead to increased selling pressure if the director chooses to exercise and sell the shares.
• The repricing could be perceived negatively by investors if it is seen as a sign of poor performance or lack of confidence in the company's future.

Industry Context

Stock option repricing is a common practice, particularly when a company's stock price has declined significantly. This action is often taken to retain key personnel and align their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option repricing is a relatively common practice in the biotech industry, especially for companies with volatile stock prices.
• Many companies in the biotech sector use stock options as a key component of executive compensation packages.
• The repricing of options to the closing price of the stock is a standard practice to ensure the options remain valuable to the recipient.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution of shares if the options are exercised.
• Employees may be impacted by the repricing of options, which could affect their own compensation packages.

Key Dates

Keywords

stock options, repricing, director, insider trading, equity incentive plan, Beyond Air, XAIR